Phase 2 Sickle Cell Disease Trial, Recruiting NCT05685368 Sponsor: Children's Hospital Los Angeles Condition: Sickle Cell Disease
Back to Sickle Cell Disease

Phase 2 Sickle Cell Disease Trial, Recruiting

NCT05685368
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 14 to 21 who have Sickle Cell Disease
  • People who are willing to take part in a group therapy program called ACT (Acceptance and Commitment Therapy), offered jointly by two hospital departments
  • People who are current patients, on the waitlist, or new patients at CHLA (Children's Hospital Los Angeles)
  • People who can understand and speak English, as the therapy is only delivered in English
  • People whose parent or guardian also speaks English
  • People who are able to give their consent or assent (agreement to take part)
  • People who are pregnant may still be eligible, provided consent can be obtained (confirm with trial site)
  • People who are developing typically for their age
  • People who have a reliable internet connection through a computer, tablet, or phone, along with a webcam and a private space for online group sessions
  • People who agree to have their initial interview recorded (audio and video)
  • People who are willing to attend 6 weekly ACT group sessions
  • People who are willing to become a member of the Community Advisory Board (CAB) — this requires agreeing to take part in the ACT program and being willing to join CAB interviews and meetings

Who may not be able to join:

  • People who are currently in prison or a youth detention centre
  • People who are unable to understand or speak English
  • People who do not have Sickle Cell Disease
  • People who are considered to be at significant risk of suicide or self-harm, as the level of support they need would interfere with the study
  • People whose families require frequent involvement from the Department of Children and Family Services
  • People who are currently experiencing psychosis
  • People with serious health concerns that would affect their ability to take part in or attend the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Xzania Lee, PhD, Children's Hospital Los Angeles

Phone: 323.361.4768

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Children's Hospital Los Angeles
Registry
ClinicalTrials.gov
Start date
1 April 2025
Est. completion
30 June 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Total Score on Index of Race-Related Stress (IRRS)-Brief Version; Sickle Cell Self-Efficacy Scale; SCD Health-Related Internalized Stigma Scale; Transition Readiness Assessment Questionnaire (TRAQ),

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov